Eli Lilly and Company $LLY Stock: Courier Capital LLC Grows Stake

Courier Capital LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 73.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,112 shares of the company’s stock after buying an additional 3,443 shares during the quarter. Eli Lilly and Company accounts for about 1.8% of Courier Capital LLC’s investment portfolio, making the stock its 12th largest position. Courier Capital LLC’s holdings in Eli Lilly and Company were worth $9,386,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the business. Catalyst Private Wealth LLC boosted its stake in shares of Eli Lilly and Company by 4.5% during the 3rd quarter. Catalyst Private Wealth LLC now owns 628 shares of the company’s stock worth $727,000 after acquiring an additional 27 shares in the last quarter. Lincoln Capital Corp raised its position in shares of Eli Lilly and Company by 21.4% during the third quarter. Lincoln Capital Corp now owns 255 shares of the company’s stock worth $295,000 after purchasing an additional 45 shares during the period. Koesten Hirschmann & Crabtree INC. raised its position in shares of Eli Lilly and Company by 81.8% during the third quarter. Koesten Hirschmann & Crabtree INC. now owns 789 shares of the company’s stock worth $913,000 after purchasing an additional 355 shares during the period. Cascade Investment Group Inc. raised its position in shares of Eli Lilly and Company by 2.4% during the third quarter. Cascade Investment Group Inc. now owns 426 shares of the company’s stock worth $493,000 after purchasing an additional 10 shares during the period. Finally, First County Bank CT lifted its holdings in shares of Eli Lilly and Company by 5.9% during the third quarter. First County Bank CT now owns 1,397 shares of the company’s stock valued at $1,616,000 after purchasing an additional 78 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide is the key catalyst ahead of the Oct. 29 earnings report. Investors may focus less on the quarterly results than on progress for retatrutide, Lilly’s next-generation obesity candidate, which could potentially become a larger growth driver than Zepbound. Eli Lilly earnings and retatrutide article
• Positive Sentiment: Analysts see earnings upside. Erste Group raised its FY2026 EPS estimate to $36.55 from $36.45 and its FY2027 estimate to $47.30. RBC also reaffirmed an “Outperform” rating with a $1,500 price target, citing strong diabetes and weight-loss demand.
• Positive Sentiment: Lilly expanded its oncology pipeline. Prelude Therapeutics will test its experimental breast-cancer drug PRT13722 with Lilly’s Verzenio and Inluriyo, with Phase 1 enrollment expected to begin in the fourth quarter of 2026. The collaboration is early-stage but adds potential long-term pipeline value. Prelude and Lilly clinical trial collaboration
• Neutral Sentiment: Combination-treatment data were encouraging but mixed. Taltz plus Zepbound produced greater weight loss and improved psoriasis outcomes than standard treatment, while another obesity-drug combination generated more weight loss but also substantially higher discontinuation rates. Tolerability and patient persistence remain important commercial questions.
• Negative Sentiment: Valuation leaves limited room for disappointment. Lilly trades at a substantial premium to large pharmaceutical peers, so investors may be taking profits while awaiting earnings confirmation. Retatrutide’s clinical execution, pricing, and future pipeline success are increasingly important to justify the valuation.

Eli Lilly and Company Trading Down 1.3%

NYSE LLY traded down $15.61 on Tuesday, hitting $1,167.01. 1,843,111 shares of the stock were exchanged, compared to its average volume of 2,952,320. Eli Lilly and Company has a 52-week low of $783.85 and a 52-week high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market capitalization of $1.10 trillion, a price-to-earnings ratio of 39.16, a P/E/G ratio of 1.47 and a beta of 0.46. The company’s 50-day moving average price is $1,175.57 and its two-hundred day moving average price is $1,100.31.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the business earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts predict that Eli Lilly and Company will post 36.19 EPS for the current year.

Analysts Set New Price Targets

LLY has been the subject of a number of recent analyst reports. Berenberg Bank set a $1,400.00 price target on Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, September 15th. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. TD Cowen restated a “buy” rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research note on Monday, September 28th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,313.43.

Insider Transactions at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 over the last quarter. Company insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.